Key clinical point:
Major finding: Clinical response rates in cohorts 1 and 2 were 65% and 69%, respectively.
Study details: Preliminary findings in 33 patients from a phase 2a trial.
Disclosures: The trial is sponsored by Kadmon. Dr. Lazaryan reported advisory board membership and consultancy for GLyPharma Therapeutic.
Source: Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.
Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.
This Week's Must Reads
Caplacizumab approved for adults with aTTP , FDA news release: FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder
IVIG versus anti-D in pediatric ITP , Lioger B et al. J Pediatr. 2019; 204:225-33.
Promising treatment for heavy menstrual bleeding , O’Brien SH et al. J Pediatr Adol Gynec. 2019 Feb 4. doi: 10.1016/j.jpag.2019.01.009.
Beware of ICH in severe hemophilia cases , Zwagemaker AF et al. EAHAD 2019, Abstract OR08.
75 exposure days is the magic number in inhibitor risk , van den Berg HM et al. EAHAD 2019, Abstract OR05.
Must Reads in Cellular Therapy
Tisagenlecleucel responses persist at 18 months in r/r B-cell ALL, Grupp SA et al. ASH 2018, Abstract 895
Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301
HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820